Frank Litvack - Aug 14, 2023 Form 4 Insider Report for CAPRICOR THERAPEUTICS, INC. (CAPR)

Role
Director
Signature
/s/ Linda Marban, Attorney-in-Fact
Stock symbol
CAPR
Transactions as of
Aug 14, 2023
Transactions value $
-$6
Form type
4
Date filed
8/16/2023, 05:00 PM
Previous filing
Feb 23, 2023
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CAPR Common Stock Options Exercise $28.8K +20.7K +17.75% $1.39 138K Aug 14, 2023 Direct F1
transaction CAPR Common Stock Tax liability -$28.8K -4.36K -3.17% $6.61 133K Aug 14, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CAPR Stock Option (Right to Buy) Options Exercise $0 -20.7K -100% $0.00* 0 Aug 14, 2023 Common Stock 20.7K $1.39 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amount has been adjusted to correct an administrative error in the Form 4 filed by the reporting person on February 23, 2023, which inadvertently overstated the amount of common stock beneficially owned by 20,391 shares.
F2 Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on August 14, 2023 of $6.61. The options would otherwise expire on August 21, 2023, pursuant to their terms.
F3 This option was granted on August 21, 2013 and was previously reported as covering 207,485 shares at an exercise price of $0.30 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
F4 The stock option award is fully vested and exercisable.